Universe Pharmaceuticals INC (UPC)
NASDAQ: UPC · Real-Time Price · USD
3.480
-0.057 (-1.62%)
At close: Aug 1, 2025, 4:00 PM
3.500
+0.020 (0.57%)
After-hours: Aug 1, 2025, 7:26 PM EDT

Company Description

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sells of traditional Chinese medicine derivative products in China.

The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.

It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule.

In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements.

It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China.

Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.

Universe Pharmaceuticals INC
Universe Pharmaceuticals INC logo
CountryChina
Founded1998
IPO DateMar 23, 2021
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees225
CEOGang Lai

Contact Details

Address:
265 Jingjiu Avenue, Jinggangshan Eco & Tech Dev Zn
Ji'An, 343100
China
Phone86 79 6840 3309
Websiteuniverse-pharmacy.com

Stock Details

Ticker SymbolUPC
ExchangeNASDAQ
Fiscal YearOctober - September
Reporting CurrencyUSD
IPO Price$5.00
CIK Code0001809616
CUSIP NumberG9442G104
ISIN NumberKYG9442G1120
SIC Code2834

Key Executives

NamePosition
Gang LaiChief Executive Officer and Chairman
Lin YangChief Financial Officer and Director
Baochang LiuChief Operating Officer

Latest SEC Filings

DateTypeTitle
Jul 29, 20256-KReport of foreign issuer
Jul 3, 20256-KReport of foreign issuer
May 15, 2025SCHEDULE 13G/AFiling
Apr 29, 202520-FAnnual and transition report of foreign private issuers
Mar 20, 20256-KReport of foreign issuer
Mar 11, 20256-KReport of foreign issuer
Mar 3, 20256-KReport of foreign issuer
Feb 25, 20256-KReport of foreign issuer
Feb 20, 20256-KReport of foreign issuer
Feb 18, 20256-KReport of foreign issuer